Home MAPK -Stem Cells & Wnt ERK

ERK

Isoform-selective Products

Signaling Pathway

ERK Signaling Pathway

ERK Products

  • All (66)
  • ERK Inhibitors (48)
  • ERK Activators (7)
  • ERK Agonist (1)
  • ERK Modulators (3)
  • New ERK Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1013 Bortezomib Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
Signal Transduct Target Ther, 2025, 10(1):81
Cell Host Microbe, 2025, 33(4):512-528.e7
ACS Nano, 2025, 19(12):11684-11701
S7101 SCH772984 SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Nat Commun, 2025, 16(1):4201
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220
Cell Death Dis, 2025, 16(1):328
S1014 Bosutinib Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Blood Adv, 2025, bloodadvances.2024015364
Virulence, 2025, 16(1):2489751
Elife, 2024, 12RP92324
S1531 BIX 02189 BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.
PLoS One, 2024, 19(1):e0295629
Nat Commun, 2023, 10.1038/s41467-023-43369-x
Exp Mol Med, 2023, 55(6):1247-1257
S1396 Resveratrol Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
Front Immunol, 2025, 16:1515605
Int J Mol Sci, 2025, 26(2)851
Biochem Biophys Res Commun, 2024, 723:150186
S7554 Ravoxertinib (GDC-0994) Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Cell Host Microbe, 2025, 33(4):512-528.e7
J Exp Clin Cancer Res, 2025, 44(1):68
J Neuroinflammation, 2025, 22(1):32
S7854 Ulixertinib (BVD-523) Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Nature, 2024, 629(8013):927-936
Acta Pharm Sin B, 2024, 14(3):1187-1203
J Adv Res, 2024, 60:141-157
S8534 Temuterkib (LY3214996) Temuterkib (LY3214996) is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.
Fluids Barriers CNS, 2025, 22(1):8
Nat Commun, 2024, 15(1):2581
Nat Commun, 2024, 15(1):7037
S7524 FR 180204 FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively. It is 30-fold less potent against the related kinase p38α and failed to inhibit any kinases(MEK1, MKK4, IKKα, PKCα, Src, Syc, and PDGFα) at less than 30 μM.
Cell Res, 2025, 10.1038/s41422-025-01085-9
Biomaterials, 2025, 317:123090
Nat Commun, 2024, 15(1):10170
S7525 XMD8-92 XMD8-92 is a potent and selective dual inhibitor of big map kinase (BMK1, ERK5) and bromodomain-containing proteins (BRDs, BET) with Kd of 80 nM and 170 nM for ERK5 and BRD4(1), respectively.
Stem Cell Reports, 2024, S2213-6711(24)00216-9
Mol Biol Rep, 2024, 51(1):313
Nat Commun, 2023, 10.1038/s41467-023-43369-x
S7709 VX-11e VX-11e (VTX-11e, Vertex-11e) is a potent, selective, and orally bioavailable ERK inhibitor with IC50 of 17 nM (ERK1) and 15 nM (ERK2), over 200-fold selective over other kinases tested.
J Biol Chem, 2025, 301(3):108183
Nat Commun, 2024, 15(1):2581
Nat Commun, 2024, 15(1):7037
S8708 AZD0364 (ATG-017) AZD0364 (ATG-017) is a pre-clinical ERK1/2 inhibitor with an IC50 of 0.6 nM for ERK2.
Nature, 2024, 629(8013):927-936
Elife, 2024, 12RP91507
J Clin Biochem Nutr, 2024, 74(2):97-107
S7334 ERK5-IN-1 ERK5-IN-1 (XMD17-109) is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.
JCI Insight, 2024, 9(10)e164191
Nat Commun, 2023, 14(1):3364
J Med Chem, 2021, 10.1021/acs.jmedchem.1c01096
S8701 MK-8353 (SCH900353) MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK1-ERK2-coupled assay).
J Exp Clin Cancer Res, 2023, 42(1):75
J Exp Clin Cancer Res, 2023, 42(1):75
Life Sci Alliance, 2023, 6(8)e202201685
S7921 DEL-22379 DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
Cells, 2022, 11(3)425
Cells, 2022, 11(3)425
Front Mol Biosci, 2022, 9:1030725
S3901 Astragaloside IV Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2.
Cell Transplant, 2023, 32:9636897231198167
Cell Transplant, 2023, 32:9636897231198167
Cell Cycle, 2022, 1-14
S8569 KO-947 KO-947 is a potent and selective inhibitor of ERK1/2 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling at low nanomolar concentrations.
Phytomedicine, 2022, 98:153963
CNS Neurosci Ther, 2022, 10.1111/cns.13945
Front Endocrinol (Lausanne), 2022, 13:896753
S9102 Magnolin Magnolin is a natural compound abundantly found in Magnolia flos targeting ERK1 (IC50=87 nM) and ERK2 (IC50=16.5 nM) and inhibits cell transformation induced by tumor promoters such as epidermal growth factor (EGF).
Cell Rep, 2023, 42(4):112294
Cell Adhesion & Migration, 2023, 17(1)
Connect Tissue Res, 2020, 1-10
S0881 Mitochonic acid 5 (MA-5) Mitochonic acid 5 (MA-5) reduces mitochondrial apoptosis via upregulation of mitophagy. Mitochonic acid 5 regulates mitophagy via Bnip3 through the MAPK-ERK-Yap signaling pathway. Mitochonic acid 5 modulates mitochondrial ATP synthesis.
Animals (Basel), 2024, 14(3):368.
Animals (Basel), 2024, 14(3)368
J Ovarian Res, 2022, 15(1):103
S3275 Senkyunolide I Senkyunolide I (SEI, SENI) is an orally active compound isolated from Ligusticum chuanxiong with analgesic, anti-migraine, neuroprotective, anti-oxidation and anti-apoptosis activities. Senkyunolide I (SEI, SENI) up-regulates the phosphorylation of Erk1/2 and induces Nrf2 nuclear translocation with enhanced HO-1 and NQO1 expressions. Senkyunolide I (SEI, SENI) promotes the ratio of Bcl-2/Bax and inhibits the expressions of cleaved caspase 3 and caspase 9.
iScience, 2024, 27(7):110367
World J Emerg Med, 2024, 15(3):206-213
SSRN , 2024, 10.2139/ssrn.4696834
S7752 Pluripotin (SC1) Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.
J Clin Biochem Nutr, 2024, 74(2):97-107
Antiviral Res, 2018, 157:57-67
Reprod Domest Anim, 2018, 53(5):1052-1059
E2203 DMU-212 DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities, which can induce mitotic arrest via induction of apoptosis and activation of extracellular-signal-regulated kinase1/2 (ERK1/2) protein.
Blood Sci, 2023, 5(3):160-169
S3785 Notoginsenoside R1 Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.
Food Sci Nutr, 2023, 11(12):7791-7802
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S8801 CC-90003 CC-90003 is an irreversible inhibitor of ERK1/2 with IC50s in the 10-20 nM range and shows good kinase selectivity in a 258-kinase biochemical assay.
Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221
Cell Death Discov, 2021, 7(1):375
S8896 BAY-885 BAY-885 is a highly potent and selective ERK5 inhibitor.
Bioengineered, 2022, 13(5):12888-12898
S9374 2',5'-Dihydroxyacetophenone 2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways.
Pathol Oncol Res, 2019, 25(1):301-309
S0454 Adjudin Adjudin (AF-2364), a potent male contraceptive, is a potent blocker of Cl⁻ channels. Adjudin exhibits anti-inflammatory properties by suppression of NF-κB p65 nuclear translocation and DNA binding activity as well as ERK MAPK phosphorylation.
Brain Res Bull, 2022, 182:80-89
S6596 AG-126 AG126 is a tyrosine kinase inhibitor which selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM.
J Immunol, 2019, 203(12):3225-3236
F0007New Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Rabbit mAb Mitogen-activated protein kinase 3, ERT2, Extracellular signal-regulated kinase 1, ERK-1, ERK1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, p44-MAPK, Microtubule-associated protein 2 kinase, p44-ERK1, MAPK3, PRKM3, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, ERK-2, MAP kinase isoform p42, p42-MAPK, Mitogen-activated protein kinase 2, MAP kinase 2, MAPK 2, ERK2, PRKM1, PRKM2
Phytother Res, 2022, 36(4):1678-1691
Burns Trauma, 2022, 10:tkac013
Am J Transl Res, 2019, 11(2):1030-1039
F0002 p44/42 MAPK (Erk1/2) Rabbit mAb Mitogen-activated protein kinase 3, MAP kinase 3, MAPK 3, ERT2, Extracellular signal-regulated kinase 1, ERK-1, ERK1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, p44-MAPK, Microtubule-associated protein 2 kinase, p44-ERK1, PRKM3, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, ERK-2, MAP kinase isoform p42, p42-MAPK, Mitogen-activated protein kinase 2, MAP kinase 2, MAPK 2,ERK2, PRKM1, PRKM2
F1716New Phospho-ERK1/ ERK2 (Thr 202/ Thr 185) Rabbit mAb
F1555New Phospho-Erk1 (Thr 202/ Tyr 204)/ Erk2 (Thr 185/ Tyr 187) Rabbit mAb ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187),Erk1 (pT202/pY204) + Erk2 (pT185/pY187),MAP Kinase, Activated (Diphosphorylated ERK-1&2),phospho-Erk1/2 (Thr202/Tyr204, Thr185/Tyr187)
Crit Care, 2022, 26(1):171
Phytother Res, 2022, 36(4):1678-1691
Burns Trauma, 2022, 10:tkac013
F1152New ERK1 Rabbit mAb Mitogen-activated protein kinase 3, ERT2, Extracellular signal-regulated kinase 1, ERK-1, ERK1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, p44-MAPK, Microtubule-associated protein 2 kinase, p44-ERK1, MAPK3, PRKM3, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, ERK-2, MAP kinase isoform p42, p42-MAPK, Mitogen-activated protein kinase 2, MAP kinase 2, MAPK 2, ERK2, PRKM1, PRKM2
F1637 ERK2 Rabbit mAb ERK 2,ERK2,MAP Kinase 2/Erk2,p42 MAP Kinase (Erk2)
S3940 3'-Hydroxypterostilbene 3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.
Int J Mol Sci, 2024, 25(18)9990
S0911 Hypaphorine Hypaphorine which is abundantly found in vaccaria semen, counteracts inflammation via inhibition of ERK or/and NFκB signaling pathways.
S8961 Alobresib (GS-5829) Alobresib (GS-5829) is a novel BET inhibitor that represents a highly effective therapeutics agent against recurrent/chemotherapy-resistant USC-overexpressing c-Myc. Alobresib (GS-5829) inhibits CLL cell proliferation and induces leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. Alobresib (GS-5829) also inhibits NF-κB signaling.
S0726 XMD8-85 (ERK5-IN-1) XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively.
S3242 Loureirin B Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular.
S9975 ASN007 ASN007(ERAS 007, ERK-IN-3) is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with 2 nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations.
S0949 Cucurbitacin IIb Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. Cucurbitacin IIb exhibits anti-inflammatory activity and induces apoptosis. Cucurbitacin IIb is isolated from Hemsleya amabilis.
S4884 Trans-Zeatin Trans-Zeatina ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. Trans-Zeatin inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently.
S4953 Usnic acid Usnic acid (Usniacin) is a furandione found uniquely in lichen that is used widely in cosmetics, deodorants, toothpaste and medicinal creams as well as some herbal products. It exhibits antiviral, antiprotozoal, antiproliferative, anti-inflammatory and analgesic activity. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways.
S9698 Ezatiostat Ezatiostat, a tripeptide analog of glutathione, is a peptidomimetic inhibitor of Glutathione S-transferase P1-1 (GSTP1-1). Ezatiostat activates c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2 and induces apoptosis.
E1959New RMC-4998 RMC-4998 is a tri-complex inhibitor that selectively targets the GTP-bound state of mutant KRASG12C, with high potency for KRASG12C-CYPA tri-complex formation with an IC50 of 28 nM. It strongly inhibits ERK signaling with an IC50 of 1–10 nM and attenuates AKT/MTOR and RAL pathways, leading to potent suppression of KRASG12C-driven tumor growth and can used in cancer research.
S0872 ASTX-029 ASTX-029 is an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. ASTX-029 inhibits ERK-dependent tumor cell proliferation and survival.
E1906New AX-15836 AX-15836 is a potent and selective inhibitor of ERK5 with an IC50 of 8 nM. It can be used to study number of biological processes.
E3276 Red Ginseng Extract Red Ginseng Extract is derived from Red Ginseng, which can increase the human body's anti-inflammatory and anticancer immunity.
S6920 SEA0400 SEA0400 is a selective and potent inhibitor of the Na+-Ca2+ exchanger (NCX) that inhibits Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50 of 33 nM, 5.0 nM and 8.3 nM, respectively. SEA0400 prevents sodium nitroprusside (SNP) from increasing ERK and p38 MAPK phosphorylation and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner.
S6760 LM22B-10 LM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator, LM22B-10 selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro.
Theranostics, 2024, 14(4):1561-1582
Int J Mol Sci, 2024, 25(4)2408
Sci Rep, 2024, 14(1):12090
S6882 HI-TOPK-032 HI-TOPK-032 is a potent and specific inhibitor of TOPK. HI-TOPK-032 also reduces ERK-RSK phosphorylation, regulates of the abundance of p53, cleaved caspase-7, and cleaved PARP, and induces apoptosis in cancer cells.
E0102 I-191 I-191 is a potent PAR2 antagonist that inhibits multiple PAR2-induced signaling pathways and functional responses. I-191 also inhibits ERK1/2 phosphorylation, RhoA activation, and inhibition of forskolin-stimulated cAMP accumulation induced by micromolar concentrations of biased ligand GB88.
Front Immunol, 2024, 15:1477072
S3292 (3R,8S)-Falcarindiol Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.
Antioxidants (Basel), 2024, 13(12)1533
Front Cell Infect Microbiol, 2023, 13:1128000
Front Pharmacol, 2021, 12:656697
S0844 NDMC101 NDMC101 inhibits osteoclastogenesis which also ameliorates paw swelling and inflammatory bone destruction, associating with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK.
S9075 Mulberroside A Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
S9665 Motixafortide (BL-8040) Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ～1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
E5898New SKLB-D18 SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50's of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for triple-negative breast cancer (TNBC).
S6177 CP 43 Cp 43 (Compound 43, TAO Kinase inhibitor 1, TAOK inhibitor 43) is a ATP-competitive and selective TAO Kinase inhibitor with IC50s of 11 nM and 15 nM for TAOK1 and TAOK2, respectively.
S3138 Methylthiouracil Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
E7772New Ulixertinib hydrochloride Ulixertinib hydrochloride (BVD-523 hydrochloride, VRT752271 hydrochloride) is a highly selective, ATP-competitive, and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. It also reduces A375 cell proliferation with an IC50 of 180 nM and inhibits phosphorylated ERK (pERK) and the downstream kinase RSK (pRSK) in the A375 melanoma cell line, with IC50 values of 4.1 μM and 0.14 μM, respectively.
S8831 MRTX-1257 MRTX-1257 is a potent, selective, irreversible, covalent and orally active inhibitor of KRAS G12C with IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.
E2660 Pamoic acid disodium Pamoic acid disodium, a potent GPR35 agonist with an EC50 value of 79 nM, induces GPR35a internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively, also potently recruits β-arrestin2 to GPR35 showing an antinociceptive effect.
Poult Sci, 2025, 104(2):104761
S9306 Corynoxeine Corynoxeine, which could be isolated from Uncaria rhynchophylla, is a useful and prospective compound in the prevention and treatment for vascular diseases. It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation.
S1321 Urolithin B Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.
S6786 ERK5-IN-2 ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50 of 0.82 μM and 3 μM for ERK5 and ERK5 MEF2D, respectively.
S3284 Tracheloside Tracheloside is a lignan glycoside isolated from seeds of Carthamus tinctorius with anti-estrogenic effects. Tracheloside significantly decreases the activity of alkaline phosphatase (AP) (an estrogen-inducible marker enzyme) with IC50 of 0.31 μg/ml. Tracheloside promotes keratinocyte proliferation through ERK1/2 stimulation.
S7101 SCH772984 SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Nat Commun, 2025, 16(1):4201
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220
Cell Death Dis, 2025, 16(1):328
S1014 Bosutinib Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Blood Adv, 2025, bloodadvances.2024015364
Virulence, 2025, 16(1):2489751
Elife, 2024, 12RP92324
S1531 BIX 02189 BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.
PLoS One, 2024, 19(1):e0295629
Nat Commun, 2023, 10.1038/s41467-023-43369-x
Exp Mol Med, 2023, 55(6):1247-1257
S1396 Resveratrol Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases（LOX, IC50=2.7 μM）, kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
Front Immunol, 2025, 16:1515605
Int J Mol Sci, 2025, 26(2)851
Biochem Biophys Res Commun, 2024, 723:150186
S7554 Ravoxertinib (GDC-0994) Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Cell Host Microbe, 2025, 33(4):512-528.e7
J Exp Clin Cancer Res, 2025, 44(1):68
J Neuroinflammation, 2025, 22(1):32
S7854 Ulixertinib (BVD-523) Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Nature, 2024, 629(8013):927-936
Acta Pharm Sin B, 2024, 14(3):1187-1203
J Adv Res, 2024, 60:141-157
S8534 Temuterkib (LY3214996) Temuterkib (LY3214996) is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.
Fluids Barriers CNS, 2025, 22(1):8
Nat Commun, 2024, 15(1):2581
Nat Commun, 2024, 15(1):7037
S7524 FR 180204 FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively. It is 30-fold less potent against the related kinase p38α and failed to inhibit any kinases(MEK1, MKK4, IKKα, PKCα, Src, Syc, and PDGFα) at less than 30 μM.
Cell Res, 2025, 10.1038/s41422-025-01085-9
Biomaterials, 2025, 317:123090
Nat Commun, 2024, 15(1):10170
S7525 XMD8-92 XMD8-92 is a potent and selective dual inhibitor of big map kinase (BMK1, ERK5) and bromodomain-containing proteins (BRDs, BET) with Kd of 80 nM and 170 nM for ERK5 and BRD4(1), respectively.
Stem Cell Reports, 2024, S2213-6711(24)00216-9
Mol Biol Rep, 2024, 51(1):313
Nat Commun, 2023, 10.1038/s41467-023-43369-x
S7709 VX-11e VX-11e (VTX-11e, Vertex-11e) is a potent, selective, and orally bioavailable ERK inhibitor with IC50 of 17 nM (ERK1) and 15 nM (ERK2), over 200-fold selective over other kinases tested.
J Biol Chem, 2025, 301(3):108183
Nat Commun, 2024, 15(1):2581
Nat Commun, 2024, 15(1):7037
S8708 AZD0364 (ATG-017) AZD0364 (ATG-017) is a pre-clinical ERK1/2 inhibitor with an IC50 of 0.6 nM for ERK2.
Nature, 2024, 629(8013):927-936
Elife, 2024, 12RP91507
J Clin Biochem Nutr, 2024, 74(2):97-107
S7334 ERK5-IN-1 ERK5-IN-1 (XMD17-109) is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.
JCI Insight, 2024, 9(10)e164191
Nat Commun, 2023, 14(1):3364
J Med Chem, 2021, 10.1021/acs.jmedchem.1c01096
S8701 MK-8353 (SCH900353) MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK1-ERK2-coupled assay).
J Exp Clin Cancer Res, 2023, 42(1):75
J Exp Clin Cancer Res, 2023, 42(1):75
Life Sci Alliance, 2023, 6(8)e202201685
S7921 DEL-22379 DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
Cells, 2022, 11(3)425
Cells, 2022, 11(3)425
Front Mol Biosci, 2022, 9:1030725
S3901 Astragaloside IV Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2.
Cell Transplant, 2023, 32:9636897231198167
Cell Transplant, 2023, 32:9636897231198167
Cell Cycle, 2022, 1-14
S8569 KO-947 KO-947 is a potent and selective inhibitor of ERK1/2 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling at low nanomolar concentrations.
Phytomedicine, 2022, 98:153963
CNS Neurosci Ther, 2022, 10.1111/cns.13945
Front Endocrinol (Lausanne), 2022, 13:896753
S9102 Magnolin Magnolin is a natural compound abundantly found in Magnolia flos targeting ERK1 (IC50=87 nM) and ERK2 (IC50=16.5 nM) and inhibits cell transformation induced by tumor promoters such as epidermal growth factor (EGF).
Cell Rep, 2023, 42(4):112294
Cell Adhesion & Migration, 2023, 17(1)
Connect Tissue Res, 2020, 1-10
S7752 Pluripotin (SC1) Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively.
J Clin Biochem Nutr, 2024, 74(2):97-107
Antiviral Res, 2018, 157:57-67
Reprod Domest Anim, 2018, 53(5):1052-1059
S3785 Notoginsenoside R1 Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways.
Food Sci Nutr, 2023, 11(12):7791-7802
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
S8801 CC-90003 CC-90003 is an irreversible inhibitor of ERK1/2 with IC50s in the 10-20 nM range and shows good kinase selectivity in a 258-kinase biochemical assay.
Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221
Cell Death Discov, 2021, 7(1):375
S8896 BAY-885 BAY-885 is a highly potent and selective ERK5 inhibitor.
Bioengineered, 2022, 13(5):12888-12898
S9374 2',5'-Dihydroxyacetophenone 2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways.
Pathol Oncol Res, 2019, 25(1):301-309
S0454 Adjudin Adjudin (AF-2364), a potent male contraceptive, is a potent blocker of Cl⁻ channels. Adjudin exhibits anti-inflammatory properties by suppression of NF-κB p65 nuclear translocation and DNA binding activity as well as ERK MAPK phosphorylation.
Brain Res Bull, 2022, 182:80-89
S6596 AG-126 AG126 is a tyrosine kinase inhibitor which selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM.
J Immunol, 2019, 203(12):3225-3236
S0911 Hypaphorine Hypaphorine which is abundantly found in vaccaria semen, counteracts inflammation via inhibition of ERK or/and NFκB signaling pathways.
S0726 XMD8-85 (ERK5-IN-1) XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively.
S3242 Loureirin B Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular.
S9975 ASN007 ASN007(ERAS 007, ERK-IN-3) is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with 2 nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations.
S0949 Cucurbitacin IIb Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. Cucurbitacin IIb exhibits anti-inflammatory activity and induces apoptosis. Cucurbitacin IIb is isolated from Hemsleya amabilis.
S4884 Trans-Zeatin Trans-Zeatina ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. Trans-Zeatin inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently.
S4953 Usnic acid Usnic acid (Usniacin) is a furandione found uniquely in lichen that is used widely in cosmetics, deodorants, toothpaste and medicinal creams as well as some herbal products. It exhibits antiviral, antiprotozoal, antiproliferative, anti-inflammatory and analgesic activity. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways.
E1959New RMC-4998 RMC-4998 is a tri-complex inhibitor that selectively targets the GTP-bound state of mutant KRASG12C, with high potency for KRASG12C-CYPA tri-complex formation with an IC50 of 28 nM. It strongly inhibits ERK signaling with an IC50 of 1–10 nM and attenuates AKT/MTOR and RAL pathways, leading to potent suppression of KRASG12C-driven tumor growth and can used in cancer research.
S0872 ASTX-029 ASTX-029 is an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. ASTX-029 inhibits ERK-dependent tumor cell proliferation and survival.
E1906New AX-15836 AX-15836 is a potent and selective inhibitor of ERK5 with an IC50 of 8 nM. It can be used to study number of biological processes.
S6920 SEA0400 SEA0400 is a selective and potent inhibitor of the Na+-Ca2+ exchanger (NCX) that inhibits Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50 of 33 nM, 5.0 nM and 8.3 nM, respectively. SEA0400 prevents sodium nitroprusside (SNP) from increasing ERK and p38 MAPK phosphorylation and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner.
S6882 HI-TOPK-032 HI-TOPK-032 is a potent and specific inhibitor of TOPK. HI-TOPK-032 also reduces ERK-RSK phosphorylation, regulates of the abundance of p53, cleaved caspase-7, and cleaved PARP, and induces apoptosis in cancer cells.
E0102 I-191 I-191 is a potent PAR2 antagonist that inhibits multiple PAR2-induced signaling pathways and functional responses. I-191 also inhibits ERK1/2 phosphorylation, RhoA activation, and inhibition of forskolin-stimulated cAMP accumulation induced by micromolar concentrations of biased ligand GB88.
Front Immunol, 2024, 15:1477072
S3292 (3R,8S)-Falcarindiol Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules.
Antioxidants (Basel), 2024, 13(12)1533
Front Cell Infect Microbiol, 2023, 13:1128000
Front Pharmacol, 2021, 12:656697
S9075 Mulberroside A Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38.
S9665 Motixafortide (BL-8040) Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ～1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
E5898New SKLB-D18 SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50's of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for triple-negative breast cancer (TNBC).
S6177 CP 43 Cp 43 (Compound 43, TAO Kinase inhibitor 1, TAOK inhibitor 43) is a ATP-competitive and selective TAO Kinase inhibitor with IC50s of 11 nM and 15 nM for TAOK1 and TAOK2, respectively.
S3138 Methylthiouracil Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.
E7772New Ulixertinib hydrochloride Ulixertinib hydrochloride (BVD-523 hydrochloride, VRT752271 hydrochloride) is a highly selective, ATP-competitive, and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. It also reduces A375 cell proliferation with an IC50 of 180 nM and inhibits phosphorylated ERK (pERK) and the downstream kinase RSK (pRSK) in the A375 melanoma cell line, with IC50 values of 4.1 μM and 0.14 μM, respectively.
S8831 MRTX-1257 MRTX-1257 is a potent, selective, irreversible, covalent and orally active inhibitor of KRAS G12C with IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.
S9306 Corynoxeine Corynoxeine, which could be isolated from Uncaria rhynchophylla, is a useful and prospective compound in the prevention and treatment for vascular diseases. It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation.
S1321 Urolithin B Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass.
S6786 ERK5-IN-2 ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50 of 0.82 μM and 3 μM for ERK5 and ERK5 MEF2D, respectively.
S1013 Bortezomib Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
Signal Transduct Target Ther, 2025, 10(1):81
Cell Host Microbe, 2025, 33(4):512-528.e7
ACS Nano, 2025, 19(12):11684-11701
S3275 Senkyunolide I Senkyunolide I (SEI, SENI) is an orally active compound isolated from Ligusticum chuanxiong with analgesic, anti-migraine, neuroprotective, anti-oxidation and anti-apoptosis activities. Senkyunolide I (SEI, SENI) up-regulates the phosphorylation of Erk1/2 and induces Nrf2 nuclear translocation with enhanced HO-1 and NQO1 expressions. Senkyunolide I (SEI, SENI) promotes the ratio of Bcl-2/Bax and inhibits the expressions of cleaved caspase 3 and caspase 9.
iScience, 2024, 27(7):110367
World J Emerg Med, 2024, 15(3):206-213
SSRN , 2024, 10.2139/ssrn.4696834
S3940 3'-Hydroxypterostilbene 3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways.
Int J Mol Sci, 2024, 25(18)9990
S9698 Ezatiostat Ezatiostat, a tripeptide analog of glutathione, is a peptidomimetic inhibitor of Glutathione S-transferase P1-1 (GSTP1-1). Ezatiostat activates c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2 and induces apoptosis.
E3276 Red Ginseng Extract Red Ginseng Extract is derived from Red Ginseng, which can increase the human body's anti-inflammatory and anticancer immunity.
S6760 LM22B-10 LM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator, LM22B-10 selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro.
Theranostics, 2024, 14(4):1561-1582
Int J Mol Sci, 2024, 25(4)2408
Sci Rep, 2024, 14(1):12090
E2660 Pamoic acid disodium Pamoic acid disodium, a potent GPR35 agonist with an EC50 value of 79 nM, induces GPR35a internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively, also potently recruits β-arrestin2 to GPR35 showing an antinociceptive effect.
Poult Sci, 2025, 104(2):104761
E2203 DMU-212 DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities, which can induce mitotic arrest via induction of apoptosis and activation of extracellular-signal-regulated kinase1/2 (ERK1/2) protein.
Blood Sci, 2023, 5(3):160-169
S0881 Mitochonic acid 5 (MA-5) Mitochonic acid 5 (MA-5) reduces mitochondrial apoptosis via upregulation of mitophagy. Mitochonic acid 5 regulates mitophagy via Bnip3 through the MAPK-ERK-Yap signaling pathway. Mitochonic acid 5 modulates mitochondrial ATP synthesis.
Animals (Basel), 2024, 14(3):368.
Animals (Basel), 2024, 14(3)368
J Ovarian Res, 2022, 15(1):103
S8961 Alobresib (GS-5829) Alobresib (GS-5829) is a novel BET inhibitor that represents a highly effective therapeutics agent against recurrent/chemotherapy-resistant USC-overexpressing c-Myc. Alobresib (GS-5829) inhibits CLL cell proliferation and induces leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. Alobresib (GS-5829) also inhibits NF-κB signaling.
S3284 Tracheloside Tracheloside is a lignan glycoside isolated from seeds of Carthamus tinctorius with anti-estrogenic effects. Tracheloside significantly decreases the activity of alkaline phosphatase (AP) (an estrogen-inducible marker enzyme) with IC50 of 0.31 μg/ml. Tracheloside promotes keratinocyte proliferation through ERK1/2 stimulation.
F0007New Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Rabbit mAb Mitogen-activated protein kinase 3, ERT2, Extracellular signal-regulated kinase 1, ERK-1, ERK1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, p44-MAPK, Microtubule-associated protein 2 kinase, p44-ERK1, MAPK3, PRKM3, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, ERK-2, MAP kinase isoform p42, p42-MAPK, Mitogen-activated protein kinase 2, MAP kinase 2, MAPK 2, ERK2, PRKM1, PRKM2
Phytother Res, 2022, 36(4):1678-1691
Burns Trauma, 2022, 10:tkac013
Am J Transl Res, 2019, 11(2):1030-1039
F1716New Phospho-ERK1/ ERK2 (Thr 202/ Thr 185) Rabbit mAb
F1555New Phospho-Erk1 (Thr 202/ Tyr 204)/ Erk2 (Thr 185/ Tyr 187) Rabbit mAb ERK1 (phospho T202 + Y204) + ERK2 (phospho T185 + Y187),Erk1 (pT202/pY204) + Erk2 (pT185/pY187),MAP Kinase, Activated (Diphosphorylated ERK-1&2),phospho-Erk1/2 (Thr202/Tyr204, Thr185/Tyr187)
Crit Care, 2022, 26(1):171
Phytother Res, 2022, 36(4):1678-1691
Burns Trauma, 2022, 10:tkac013
F1152New ERK1 Rabbit mAb Mitogen-activated protein kinase 3, ERT2, Extracellular signal-regulated kinase 1, ERK-1, ERK1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, p44-MAPK, Microtubule-associated protein 2 kinase, p44-ERK1, MAPK3, PRKM3, Mitogen-activated protein kinase 1, MAP kinase 1, MAPK 1, ERT1, Extracellular signal-regulated kinase 2, ERK-2, MAP kinase isoform p42, p42-MAPK, Mitogen-activated protein kinase 2, MAP kinase 2, MAPK 2, ERK2, PRKM1, PRKM2
E1959New RMC-4998 RMC-4998 is a tri-complex inhibitor that selectively targets the GTP-bound state of mutant KRASG12C, with high potency for KRASG12C-CYPA tri-complex formation with an IC50 of 28 nM. It strongly inhibits ERK signaling with an IC50 of 1–10 nM and attenuates AKT/MTOR and RAL pathways, leading to potent suppression of KRASG12C-driven tumor growth and can used in cancer research.
E1906New AX-15836 AX-15836 is a potent and selective inhibitor of ERK5 with an IC50 of 8 nM. It can be used to study number of biological processes.
E5898New SKLB-D18 SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50's of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for triple-negative breast cancer (TNBC).
E7772New Ulixertinib hydrochloride Ulixertinib hydrochloride (BVD-523 hydrochloride, VRT752271 hydrochloride) is a highly selective, ATP-competitive, and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. It also reduces A375 cell proliferation with an IC50 of 180 nM and inhibits phosphorylated ERK (pERK) and the downstream kinase RSK (pRSK) in the A375 melanoma cell line, with IC50 values of 4.1 μM and 0.14 μM, respectively.

Choose Selective ERK Inhibitors

Tags: ERK inhibitor|ERK agonist|ERK activator|ERK inducer|ERK antagonist|ERK signaling pathway|ERK assay kit